Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immunological diseases. The company entered public markets through a SPAC business combination that closed in 2022, transitioning from blank-check vehicle to operating entity within the healthcare and biotechnology sector. Zura Bio filed its first annual report on Form 10-K with the SEC on March 28, 2023, covering the fiscal year ended December 31, 2022, marking its initial full reporting cycle as a public company. Its pipeline is centered on immune-mediated conditions, with programs targeting cytokine-driven pathways. For comprehensive filing history, deal terms, and pipeline tracking on ZURA, sign up for full data on SpacDesk.